US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.68

-0.1400-7.69%

Post-market: 1.680.00000.00%19:59 EDT

Volume:825.87K

Turnover:1.41M

Market Cap:78.07M

PE:-1.60

High:1.84

Open:1.81

Low:1.66

Close:1.82

52wk High:2.32

52wk Low:1.15

Shares:46.47M

Float Shares:33.71M

Volume Ratio:0.90

T/O Rate:2.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0524

EPS(LYR):-0.9829

ROE:-914.04%

ROA:-232.65%

PB:-6.55

PE(LYR):-1.71

Loading ...

Overview Company News Filings

OS Therapies Is Maintained at Buy by Lake Street

OS Therapies price target lowered to $13 from $14 at Lake Street

OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate

Benzinga Earnings

OS Therapies Q1 FY26 net loss widens to $10.4 million; no revenue

OS Therapies Delays Quarterly SEC Filing

OS Therapies delays filing quarterly report after close process takes longer

OS Therapies to report Q1 2026 financial results, give business update

Stonegate Capital Partners updates coverage on OS Therapies

OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street

OS Therapies Gains EMA Rolling Review for OST-HER2

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies says EMA starts rolling review for OST-HER2 conditional approval application

OS Therapies files patent application for Listeria immune-response biomarker signature

OS Therapies reports Phase 2b biomarker signature tied to OST-HER2 survival outcomes

OS Therapies appoints Moderna co-founder Robert Langer as strategic advisor

OS Therapies appoints Guardant Health CMO Craig Eagle to strategic advisory board

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies bolsters funding to advance OST-HER2 program

OS Therapies completes USD 5.25 million registered direct offering

OS Therapies Files Prospectus Supplement for Share Resale

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/OSTX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.68,"timestamp":1789156800000,"preClose":1.82,"halted":0,"volume":825871,"hourTrading":{"tag":"盘后","latestPrice":1.68,"preClose":1.68,"latestTime":"19:59 EDT","volume":10096,"amount":16937.7854,"timestamp":1789171167215,"change":0,"changeRate":0,"amplitude":0.017321},"delay":0,"changeRate":-0.07692307692307698,"floatShares":33708100,"shares":46470790,"eps":-1.05241,"marketStatus":"Market Closed","change":-0.14,"latestTime":"09-11 16:00:00 EDT","open":1.81,"high":1.8399,"low":1.66,"amount":1413102.1974337,"amplitude":0.098846,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05241,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.82,"preHourTrading":{"tag":"盘前","latestPrice":1.77,"preClose":1.82,"latestTime":"09:29 EDT","volume":10425,"amount":18653.244,"timestamp":1789133363266,"change":-0.05,"changeRate":-0.027473,"amplitude":0.043956},"postHourTrading":{"tag":"盘后","latestPrice":1.68,"preClose":1.68,"latestTime":"19:59 EDT","volume":10096,"amount":16937.7854,"timestamp":1789171167215,"change":0,"changeRate":0,"amplitude":0.017321},"volumeRatio":0.9004742073672523},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":33708100,"roa":"-232.65%","roe":"-914.04%","lyrEps":-0.982926,"volumeRatio":0.9004742073672523,"shares":46470790,"dividePrice":0,"high":1.8399,"amplitude":0.098846,"preClose":1.82,"low":1.66,"week52Low":1.15,"pbRate":"-6.55","week52High":2.322,"institutionHeld":0,"latestPrice":1.68,"eps":-1.05241,"divideRate":0,"volume":825871,"delay":0,"ttmEps":-1.05241,"open":1.81,"prevYearClose":1.4,"prevWeekClose":1.88,"prevMonthClose":1.69,"prevQuarterClose":1.9,"fiveDayClose":1.82,"twentyDayClose":1.6,"sixtyDayClose":1.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1783656000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2026-09-11","current":-1.596336,"percent":0.889098,"low":-14.897496,"twenty":-7.50649,"median":-4.384839,"eighty":-2.485411,"high":-1.629046,"avg":-5.123237,"sd":3.235907,"marketCap":83949001},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-31","current":-4.156353,"twenty":-9.977535,"median":-5.177924,"eighty":-4.412988,"marketCap":59352507},{"date":"2025-11-07","current":-4.273765,"twenty":-9.834079,"median":-5.118748,"eighty":-4.402429,"marketCap":61029131},{"date":"2025-11-14","current":-4.273765,"twenty":-9.766275,"median":-5.104544,"eighty":-4.391176,"marketCap":61029131},{"date":"2025-11-21","current":-2.971008,"twenty":-9.761488,"median":-5.059977,"eighty":-4.38129,"marketCap":54322633},{"date":"2025-11-28","current":-3.447432,"twenty":-9.750618,"median":-5.0362,"eighty":-4.358965,"marketCap":63033690},{"date":"2025-12-05","current":-3.50521,"twenty":-9.73315,"median":-4.994703,"eighty":-4.321289,"marketCap":64090120},{"date":"2025-12-12","current":-3.909657,"twenty":-9.718269,"median":-4.969558,"eighty":-4.300776,"marketCap":71485134},{"date":"2025-12-19","current":-3.081503,"twenty":-9.704683,"median":-4.950787,"eighty":-4.273765,"marketCap":56342963},{"date":"2025-12-26","current":-2.927428,"twenty":-9.698213,"median":-4.936226,"eighty":-4.231496,"marketCap":53525815},{"date":"2026-01-02","current":-2.696315,"twenty":-9.672334,"median":-4.919621,"eighty":-4.226786,"marketCap":49300092},{"date":"2026-01-09","current":-2.965947,"twenty":-9.672334,"median":-4.910716,"eighty":-4.157441,"marketCap":54230102},{"date":"2026-01-16","current":-2.811872,"twenty":-9.575287,"median":-4.897871,"eighty":-4.145979,"marketCap":51412953},{"date":"2026-01-23","current":-2.831131,"twenty":-9.549408,"median":-4.897461,"eighty":-4.087363,"marketCap":51765097},{"date":"2026-01-30","current":-2.657797,"twenty":-9.439422,"median":-4.891008,"eighty":-3.973179,"marketCap":48595805},{"date":"2026-02-06","current":-2.445943,"twenty":-9.413543,"median":-4.875301,"eighty":-3.908145,"marketCap":44722227},{"date":"2026-02-13","current":-2.23409,"twenty":-9.413543,"median":-4.874269,"eighty":-3.823969,"marketCap":40848648},{"date":"2026-02-20","current":-2.311128,"twenty":-9.35512,"median":-4.850347,"eighty":-3.774842,"marketCap":42257222},{"date":"2026-02-27","current":-2.754094,"twenty":-9.300118,"median":-4.8312,"eighty":-3.691488,"marketCap":50356523},{"date":"2026-03-06","current":-2.908169,"twenty":-9.286254,"median":-4.804944,"eighty":-3.509217,"marketCap":53173671},{"date":"2026-03-13","current":-2.927428,"twenty":-9.264738,"median":-4.804459,"eighty":-3.458987,"marketCap":53525815},{"date":"2026-03-20","current":-2.888909,"twenty":-9.232389,"median":-4.792605,"eighty":-3.347283,"marketCap":52821528},{"date":"2026-03-27","current":-2.638537,"twenty":-9.139288,"median":-4.763734,"eighty":-3.283217,"marketCap":48243662},{"date":"2026-04-02","current":-1.869843,"twenty":-9.07459,"median":-4.734863,"eighty":-3.19573,"marketCap":53765188},{"date":"2026-04-10","current":-1.973708,"twenty":-9.037738,"median":-4.706449,"eighty":-3.15544,"marketCap":56751705},{"date":"2026-04-17","current":-2.046809,"twenty":-9.001875,"median":-4.699192,"eighty":-3.081503,"marketCap":58853620},{"date":"2026-04-24","current":-2.119909,"twenty":-8.908899,"median":-4.683564,"eighty":-3.034837,"marketCap":60955535},{"date":"2026-05-01","current":-2.485411,"twenty":-8.768822,"median":-4.677121,"eighty":-2.985206,"marketCap":71465110},{"date":"2026-05-08","current":-2.485411,"twenty":-8.7364,"median":-4.657962,"eighty":-2.965947,"marketCap":71465110},{"date":"2026-05-15","current":-2.748572,"twenty":-8.699253,"median":-4.619378,"eighty":-2.954392,"marketCap":79032004},{"date":"2026-05-22","current":-2.169023,"twenty":-8.649859,"median":-4.610947,"eighty":-2.927428,"marketCap":76509706},{"date":"2026-05-29","current":-2.500026,"twenty":-8.617798,"median":-4.590507,"eighty":-2.912021,"marketCap":88185449},{"date":"2026-06-05","current":-2.335883,"twenty":-8.605027,"median":-4.574874,"eighty":-2.888909,"marketCap":82395496},{"date":"2026-06-12","current":-2.159113,"twenty":-8.590585,"median":-4.542637,"eighty":-2.850391,"marketCap":76160161},{"date":"2026-06-18","current":-2.17174,"twenty":-8.57247,"median":-4.525147,"eighty":-2.831131,"marketCap":76605542},{"date":"2026-06-26","current":-2.272751,"twenty":-8.516979,"median":-4.520733,"eighty":-2.811872,"marketCap":80168590},{"date":"2026-07-02","current":-2.285377,"twenty":-8.509613,"median":-4.508587,"eighty":-2.790024,"marketCap":80613971},{"date":"2026-07-10","current":-2.17174,"twenty":-8.507772,"median":-4.481912,"eighty":-2.769501,"marketCap":76605542},{"date":"2026-07-17","current":-1.893959,"twenty":-8.481893,"median":-4.461622,"eighty":-2.745824,"marketCap":66807159},{"date":"2026-07-24","current":-1.969717,"twenty":-8.439377,"median":-4.448354,"eighty":-2.715575,"marketCap":69479445},{"date":"2026-07-31","current":-1.969717,"twenty":-8.312777,"median":-4.438389,"eighty":-2.696315,"marketCap":69479445},{"date":"2026-08-07","current":-2.058102,"twenty":-8.184914,"median":-4.437352,"eighty":-2.657797,"marketCap":72597112},{"date":"2026-08-14","current":-2.020223,"twenty":-8.139646,"median":-4.419971,"eighty":-2.618363,"marketCap":71260969},{"date":"2026-08-21","current":-1.787426,"twenty":-8.123117,"median":-4.411096,"eighty":-2.573055,"marketCap":70370207},{"date":"2026-08-28","current":-1.968306,"twenty":-7.906822,"median":-4.400554,"eighty":-2.529271,"marketCap":77491386},{"date":"2026-09-04","current":-2.132332,"twenty":-7.610426,"median":-4.389861,"eighty":-2.500031,"marketCap":83949001},{"date":"2026-09-11","current":-2.132332,"twenty":-7.50649,"median":-4.384839,"eighty":-2.485411,"marketCap":83949001}],"updateTime":1789223329713},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636852967","title":"OS Therapies Is Maintained at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2636852967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636852967?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:14","pubTimestamp":1779200040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 10:14 ET (14:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636741859","title":"OS Therapies price target lowered to $13 from $14 at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2636741859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636741859?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:45","pubTimestamp":1779194731,"startTime":"0","endTime":"0","summary":"Lake Street lowered the firm’s price target on OS Therapies (OSTX) to $13 from $14 and keeps a Buy rating on the shares following the company’s Q1 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-13-from-14-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-13-from-14-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636998022","title":"OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2636998022","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636998022?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:37","pubTimestamp":1779100669,"startTime":"0","endTime":"0","summary":"OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52628803/os-therapies-q1-eps-0-27-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636024377","title":"OS Therapies Q1 FY26 net loss widens to $10.4 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2636024377","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636024377?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:06","pubTimestamp":1779098791,"startTime":"0","endTime":"0","summary":"OS Therapies posted a net loss of USD 10.4 million for the three months ended March 31, 2026, widening from USD 3.9 million a year earlier as the operating loss grew to USD 10.17 million from USD 5 million.Research and development expense climbed to USD 7.35 million from USD 1.31 million, while general and administrative expense fell to USD 2.82 million from USD 3.69 million.Other expense totaled USD 228,893 versus other income of USD 1.12 million, reflecting USD 75,344 of interest expense and USD 153,594 of non-operating expense; there was no revenue in either period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL3mpSjd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635056321","title":"OS Therapies Delays Quarterly SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635056321","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635056321?lang=en_us&edition=fundamental","pubTime":"2026-05-16 07:30","pubTimestamp":1778887821,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has released a notification of late filing. OS Therapies Incorporated has filed a Form 12b-25 notifying inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635303250","title":"OS Therapies delays filing quarterly report after close process takes longer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635303250","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635303250?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:25","pubTimestamp":1778876701,"startTime":"0","endTime":"0","summary":"OS Therapies filed a Form 12b-25 to delay its quarterly report on Form 10-Q for period ended March 31, 2026.Filing missed May 15 due date due to delays in compiling and reviewing information tied to a longer financial close process.Report expected within five calendar days of original deadline under SEC Rule 12b-25.Notice indicated no anticipated significant change in results of operations versus the year-earlier quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8LHvw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037956","title":"OS Therapies to report Q1 2026 financial results, give business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037956?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:07","pubTimestamp":1778875642,"startTime":"0","endTime":"0","summary":"OS Therapies to release first-quarter 2026 financial results, followed by business update, on Monday, May 18, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7KBg36:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635244596","title":"Stonegate Capital Partners updates coverage on OS Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2635244596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635244596?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:36","pubTimestamp":1778610977,"startTime":"0","endTime":"0","summary":"Stonegate Capital Partners updated coverage on OS Therapies, citing increased regulatory visibility for lead candidate OST-HER2 in recurrent, fully resected pulmonary metastatic osteosarcoma.EMA initiated a rolling review for a Conditional Marketing Authorization dossier, while EMA and Australia’s TGA aligned on 3-year overall survival as approvable efficacy endpoint.Focus shifts to upcoming survival readouts, with 2.5-year overall survival data due mid-2Q26 and 3-year data expected early 4Q26 ahead of a potential EMA CMA decision in 4Q26.Funding runway highlighted, including a USD 5.25 million raise and an expected USD 4 million in non-dilutive funding, with a potential priority review voucher cited as additional approval-contingent upside.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4d2ZM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632643704","title":"OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2632643704","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632643704?lang=en_us&edition=fundamental","pubTime":"2026-05-01 23:35","pubTimestamp":1777649750,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on OS Therapies Incorporated, with a price target of $14.00. Messe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-gets-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-gets-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664219","title":"OS Therapies Gains EMA Rolling Review for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664219?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:18","pubTimestamp":1777583885,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has issued an announcement. On April 30, 2026, OS Therapies announced that the European Medicines Agency has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","OSTX","BK4139","BK4148","EMA","OST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631320466","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2631320466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631320466?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:33","pubTimestamp":1777552380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 08:33 ET (12:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631870086","title":"OS Therapies says EMA starts rolling review for OST-HER2 conditional approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2631870086","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631870086?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:20","pubTimestamp":1777544430,"startTime":"0","endTime":"0","summary":"EMA started rolling review of OST-HER2 conditional marketing authorization filing from OS Therapies for prevention or delay of recurrence in fully resected pulmonary metastatic osteosarcoma.Review will be completed using 3-year overall survival data, with OS Therapies targeting an EMA decision in Q4 2026.Australia TGA invited a provisional determination application, with a rolling review decision expected after a Phase 3 clinical trial notification later in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1NN0fY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627297982","title":"OS Therapies files patent application for Listeria immune-response biomarker signature","url":"https://stock-news.laohu8.com/highlight/detail?id=2627297982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627297982?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:37","pubTimestamp":1776339467,"startTime":"0","endTime":"0","summary":"OS Therapies filed patent application covering biomarkers tied to immune response to its Listeria monocytogenes platform.Filing targets treatment-emergent immune signature linked to downregulation of tumor immune-evasion genes.Application also covers upregulation of genes associated with cytotoxic cellular immune activation.Biomarker signature was identified using data from Phase 2b trial of OST-HER2 in fully resected pulmonary metastatic osteosarcoma.OS Therapies plans conference call later in April 2026 to review biomarker signature data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9fcgtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627729244","title":"OS Therapies reports Phase 2b biomarker signature tied to OST-HER2 survival outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2627729244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627729244?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:21","pubTimestamp":1776338460,"startTime":"0","endTime":"0","summary":"OS Therapies filed a new patent application covering a treatment-emergent immune biomarker signature tied to response in its Phase 2b trial of OST-HER2 in resected pulmonary metastatic osteosarcoma.Biomarker findings were not yet presented; management plans a conference call later in April 2026 to review the signature and its link to clinical outcomes.Company reported that patients showing the signature were the ones who achieved longer-term survival outcomes, supporting its strategy to use the biomarker as a surrogate endpoint in regulatory filings.OS Therapies targets a Biologics License Application under FDA Accelerated Approval in second half of 2026, positioning the biomarker as decision-driving evidence for earlier market access.Priority Review Voucher economics remain central to upside case, with most recent disclosed transaction in February 2026 valued at USD 205 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL379nG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627431812","title":"OS Therapies appoints Moderna co-founder Robert Langer as strategic advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627431812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627431812?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:02","pubTimestamp":1776074546,"startTime":"0","endTime":"0","summary":"OS Therapies appointed Robert “Bob” S. Langer to its strategic advisory board.Langer is an MIT Institute Professor who co-founded Moderna.He will advise on prioritizing OS Therapies’ listeria-oncology pipeline.Mandate includes evaluating combinations with other oncology technologies.Scope also covers selection of tunable antibody-drug conjugate candidates for further development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4ywHk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4501","BK4532","MRNA","BK4585","BK4568","BK4551","BK4533","BK4534","OSTX","MRNX","BK4548","MRNY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625287579","title":"OS Therapies appoints Guardant Health CMO Craig Eagle to strategic advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2625287579","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625287579?lang=en_us&edition=fundamental","pubTime":"2026-04-08 23:39","pubTimestamp":1775662754,"startTime":"0","endTime":"0","summary":"OS Therapies appointed Craig Eagle, MD to newly formed strategic advisory board on April 8, 2026.Mandate includes pipeline prioritization beyond osteosarcoma as company advances clinical-stage oncology programs.Eagle is Chief Medical Officer at Guardant Health.Career background includes senior oncology leadership roles at Genentech, Pfizer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9HT053:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU1894683264.USD","LU0985481810.HKD","IE0002270589.USD","BK4592","BK4007","LU1057294990.SGD","BK4139","BK4588","IE000M9KFDE8.USD","LU0868494617.USD","SG9999002224.SGD","LU0321505439.SGD","OSTX","LU0306806265.USD","BK4585","LU0170899867.USD","LU0456855351.SGD","SG9999001176.SGD","SG9999003800.SGD","SG9999001176.USD","SG9999013999.USD","BK4196","LU1023059063.AUD","BK4535","IE00BBT3K403.USD","LU0306807586.USD","LU1883839398.USD","LU0225771236.USD","IE00BLSP4452.SGD","BK4551","SG9999002232.USD","BK4550","BK4581","BK4534","LU0225284248.USD","LU0289739699.SGD","LU1894683348.USD","SGXZ57979304.SGD","BK4533","BK4599","LU0058720904.USD","LU1066053197.SGD","LU0122379950.USD","LU0234572021.USD","BK4568","SG9999011175.SGD","GH","LU0321505868.SGD","IE00B19Z3B42.SGD","LU1066051498.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625794607","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2625794607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625794607?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:14","pubTimestamp":1775650440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 08:14 ET (12:14 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624638977","title":"OS Therapies bolsters funding to advance OST-HER2 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2624638977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624638977?lang=en_us&edition=fundamental","pubTime":"2026-04-03 06:40","pubTimestamp":1775169600,"startTime":"0","endTime":"0","summary":"An update from OS Therapies Incorporated ( ($OSTX) ) is now available. On March 31, 2026, OS Therapies entered into a securities purchase agreement...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","OST","BK4139","BK4097","OS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624766687","title":"OS Therapies completes USD 5.25 million registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624766687","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624766687?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:15","pubTimestamp":1775164555,"startTime":"0","endTime":"0","summary":"OS Therapies completed a registered direct follow-on offering raising USD 5.25 million from primarily pre-existing high-net-worth investors.Deal priced at USD 1.40 per share, or USD 1.399 per pre-funded warrant.Investors also received warrants exercisable at USD 1.40 per share.Company expects about USD 2 million in VAT refunds in 2Q-26 from its U.K. subsidiary.Management forecasts about USD 2 million in U.K. R&D tax credits in 2H-26, extending cash runway into 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL4BmSv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624552529","title":"OS Therapies Files Prospectus Supplement for Share Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2624552529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624552529?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:07","pubTimestamp":1775002053,"startTime":"0","endTime":"0","summary":"The latest update is out from OS Therapies Incorporated ( ($OSTX) ). On March 31, 2026, OS Therapies Incorporated filed a prospectus supplement wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OS","OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":67,"code":"91000000","status":"200"}]}}